A phase I study of nanoliposomal irinotecan and 5-fluorouracil/folinic acid in combination with interleukin-1-alpha antagonist for advanced pancreatic cancer patients with cachexia (OnFX).

被引：0
|
作者：
Hendifar, Andrew Eugene
Kim, Sungjin
Tighiouart, Mourad
Hautamaki, Emily
Kim, Haesoo
Ng, Camille
Liu, Jar-Yee
Scher, Kevin S.
Klempner, Samuel J.
Placencio-Hickok, Veronica
Gresham, Gillian
Gong, Jun
机构：
[1] Cedars Sinai Med Ctr, Samuel Oschin Canc Ctr, Los Angeles, CA 90048 USA
[2] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[3] Cedars Sinai Med Ctr, West Hollywood, CA USA
[4] Tower Hematol Oncol Med Grp, Beverly Hills, CA USA
[5] Angeles Clin & Res Inst, Los Angeles, CA USA
[6] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4634
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A phase I study of nanoliposomal irinotecan and 5-fluorouracil/folinic acid in combination with interleukin-1-alpha antagonist for advanced pancreatic cancer patients with cachexia (OnFX)
    Atkins, Katelyn Mae
    Gong, Jun
    Tighiouart, Mourad
    Klempner, Samuel J.
    Tuli, Richard
    Placencio-Hickok, Veronica
    Hendifar, Andrew Eugene
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [2] Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
    Jun Gong
    Shant Thomassian
    Sungjin Kim
    Gillian Gresham
    Natalie Moshayedi
    Jason Y. Ye
    Julianne C. Yang
    Jonathan P. Jacobs
    Simon Lo
    Nick Nissen
    Srinivas Gaddam
    Mourad Tighiouart
    Arsen Osipov
    Andrew Hendifar
    Scientific Reports, 12
  • [3] Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
    Gong, Jun
    Thomassian, Shant
    Kim, Sungjin
    Gresham, Gillian
    Moshayedi, Natalie
    Ye, Jason Y.
    Yang, Julianne C.
    Jacobs, Jonathan P.
    Lo, Simon
    Nissen, Nick
    Gaddam, Srinivas
    Tighiouart, Mourad
    Osipov, Arsen
    Hendifar, Andrew
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [4] Phase I study of gemcitabine in combination with cisplatin, 5-fluorouracil and folinic acid in patients with advanced esophageal cancer
    Oettle, H
    Arnold, D
    Kern, M
    Hoepffner, N
    Settmacher, U
    Neuhaus, P
    Riess, H
    ANTI-CANCER DRUGS, 2002, 13 (08) : 833 - 838
  • [5] Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma -: A phase I study
    Garufi, G
    Dogliotti, L
    D'Attino, RM
    Tampellini, M
    Aschelter, AM
    Pugliese, P
    Perrone, M
    Nisticó, C
    Comis, S
    Terzoli, E
    CANCER, 2001, 91 (04) : 712 - 720
  • [6] A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients
    C Garufi
    E Bria
    B Vanni
    A M R Zappalà
    I Sperduti
    E Terzoli
    British Journal of Cancer, 2003, 89 : 1870 - 1875
  • [7] A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients
    Garufi, C
    Bria, E
    Vanni, B
    Zappalà, AMR
    Sperduti, I
    Terzoli, E
    BRITISH JOURNAL OF CANCER, 2003, 89 (10) : 1870 - 1875
  • [8] An alternating regimen of irinotecan/5-fluorouracil/folinic acid and oxaliplatin/5-fluorouracil/folinic acid in metastatic colorectal cancer: A phase II trial
    Ferrari, V
    Valcamonico, F
    Amoroso, V
    Simoncini, E
    Vassalli, L
    Marpicati, P
    Rangoni, G
    Grisanti, S
    Pasinetti, N
    Marini, G
    ONCOLOGY, 2005, 69 (04) : 283 - 289
  • [9] First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer
    Hossein Taghizadeh
    Matthias Unseld
    Andreas Schmiderer
    Angela Djanani
    Klaus Wilthoner
    Dieter Buchinger
    Gerald W. Prager
    Cancer Chemotherapy and Pharmacology, 2020, 86 : 109 - 115
  • [10] First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer
    Taghizadeh, Hossein
    Unseld, Matthias
    Schmiderer, Andreas
    Djanani, Angela
    Wilthoner, Klaus
    Buchinger, Dieter
    Prager, Gerald W.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (01) : 109 - 115
12345